Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106556 | 0.89 | PSEN1 (0.30) | — | |
| SCHEMBL5105478 | 0.83 | — | — | |
| SCHEMBL3271971 | 0.82 | RXRA (0.33) | CNR1CNR2 | |
| SCHEMBL5112997 | 0.81 | — | — | |
| SCHEMBL4943359 | 0.78 | CNR1 (0.34) | CNR1CNR2 | |
| SCHEMBL5111448 | 0.78 | — | — | |
| SCHEMBL3273514 | 0.77 | CNR1 (0.34) | CNR1CNR2 | |
| SCHEMBL5489084 | 0.77 | IDO1 (0.34) | CNR1CNR2 | |
| SCHEMBL3281407 | 0.76 | CNR1 (0.33) | CNR1CNR2 | |
| SCHEMBL5494941 | 0.74 | CNR1 (0.32) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329667-B2 | A hexahydro-1,5,6,8-tetraaza-acenaphthylene or -1,3,4-triazaphenalene derivatives; treatment of depression and anxiety; inflammatory bowel disease; treatment of conditions mediated by corticotropin-releasing factor | GLAXO GROUP LIMITED (GB) | 2008-02-12 | — | — | US | disclosed |
| EP-1383498-B1 | CRF RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2006-03-15 | — | — | EP | disclosed |
| US-20040235871-A1 | Crf receptor antagonists | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235871-A1 | Crf receptor antagonists | CRHR1, CRHR2, CRH | CNR1 5/4885CNR2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.